HER2-positive or low breast cancer brain metastasis drug study
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older), and you have advanced breast cancer that is HER2-positive or HER2-low.
- You have at least one measurable brain (intracranial) tumor spot seen on scans, and it has not been treated locally yet.
- You have NOT had prior brain radiation, and you do not need urgent brain treatment now (or you choose not to get it right away).
- You are far enough out from your last cancer treatment (more than 2 weeks; and no brain-cancer treatment meds in the time windows allowed by the study).
- You can safely take study medicine based on general health and organ function, and you are expected to live at least 6 months.
- You have no major brain conditions that make emergencies likely (like cancer spread to the fluid around the brain or needing emergency neurosurgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests SHR-A1811 given before surgery (neoadjuvant treatment) for breast cancer that is hormone-receptor positive (HR-positive) and HER2-low. It aims to shrink or control the cancer early and see how well this approach works compared with standard care.
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
This trial tests two new drugs, SHR-A1811 and THPy, for women with HER2-positive advanced breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and improve outcomes for patients who have not yet had systemic treatment for advanced disease.
This study is testing a new targeted therapy for people with HER2-positive breast cancer that has spread to the brain. It aims to see if the drug can help shrink brain tumors and improve outcomes for two groups: those with cancer in the fluid around the brain and those without.
This study tests a new drug (SHR-A1811) combined with radiation therapy for breast cancer that has spread to the brain. The goal is to see if this combination can help control the brain tumors and possibly improve outcomes.
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.